Prevention & care

Barrett’s esophagus: metaplasia versus dysplasia, biopsy confirmation, surveillance, eradication therapy, and cancer-risk context

8 sources · Latest source check 2026-10-09 UTC

On this page

Barrett’s esophagus means that the esophageal lining has changed to resemble intestinal lining. This metaplasia is different from dysplasia, which describes abnormal cellular changes associated with higher progression risk. Barrett’s is not itself an esophageal-cancer diagnosis, and most people with it do not develop cancer.[1]

Tissue findings change the question

Tissue findings change the question
Finding	Why it matters
Metaplasia	A changed type of lining.[1]
No dysplasia	Barrett’s tissue without the abnormal-cell category.[1]
Indefinite for dysplasia	The pathologist cannot distinguish dysplasia confidently from inflammatory changes.[5]
Low-grade dysplasia	Requires reliable pathology confirmation before treatment decisions.[5]
High-grade dysplasia	A higher-risk category with stronger support for eradication therapy.[6]

Heartburn is not a measurement of the tissue category

NIDDK states that Barrett’s itself does not cause symptoms, though GERD may coexist and cause heartburn or regurgitation. Symptoms improving therefore does not establish that metaplasia or dysplasia has disappeared. Difficulty swallowing, unexplained weight loss, digestive bleeding or persistent vomiting need assessment rather than being dismissed as routine reflux.[2]

Risk factors guide assessment without establishing a diagnosis

NIDDK identifies reflux, age, smoking, excess abdominal weight, family history and demographic factors among associations with Barrett’s. These describe population risk patterns; they are not a checklist that makes a diagnosis, nor do they exclude disease in someone outside a commonly described group. Tissue and endoscopic assessment provide different information.[1]

Endoscopy and tissue sampling work together

NIDDK describes upper endoscopy to inspect the lining and multiple biopsies because the changes may not affect every area. A pathologist examines the tissue. Some settings also use swallowable tissue-collection devices. These methods and their availability are not interchangeable with a symptom questionnaire or a consumer test of acid exposure.[3]

Diagnostic conventions differ between professional systems

ACG’s 2022 guideline suggests requiring intestinal metaplasia and at least one centimeter of columnar lining for its Barrett’s definition. It notes that some other professional guidelines do not require the same metaplasia criterion. An irregular short Z line is therefore not automatically equivalent to established Barrett’s across all contexts. Terminology should identify which definition is being used.[5]

An expert second reading can change the clinical category

ACG recommends confirmation of dysplasia by a second pathologist with gastrointestinal expertise. Its evidence discussion describes lower agreement for low-grade or indefinite dysplasia than for clearly nondysplastic or high-grade tissue. A pathology label is clinically meaningful, but disagreement can affect the treatment question. This is one reason expert confirmation precedes irreversible treatment decisions.[5]

Repeated examination is different from removing abnormal tissue

NIDDK calls scheduled repeat endoscopy with biopsies surveillance. Its purpose is to look for concerning changes over time. The plan depends on pathology and other clinical information. A personal schedule cannot be selected from the disease name alone, and apparent symptom relief does not replace the planned assessment of the lining.[3]

The 2025 surveillance guideline makes both recommendations and nonrecommendations

AGA conditionally favors surveillance for nondysplastic Barrett’s but conditionally advises against it for columnar lining shorter than one centimeter. It emphasizes high-quality imaging, structured biopsies and expert pathology. It makes no recommendation for several enhanced sampling or biomarker approaches, including p53 and TissueCypher, because the reviewed evidence does not resolve their clinical utility.[7]

Resection and ablation have different roles

NIDDK distinguishes cutting out tissue with endoscopic mucosal resection, heat-based radiofrequency ablation and cold-based cryotherapy. Selected cases may require surgery, which is less common. These options are not equivalent responses to every finding. Removing a visible lesion and treating a remaining field of abnormal lining can answer different pathological and therapeutic questions.[4]

Guidance retains a role for patient preferences in low-grade disease

AGA’s 2024 eradication guideline states that surveillance can reasonably be chosen in low-grade dysplasia when a patient places more weight on treatment harms and less on uncertain cancer-mortality benefit. It favors focal resection plus ablation over stepwise resection in selected visible lesions. The guideline was funded by AGA, with disclosed panel interests; it is not an independent new trial.[6]

Acid suppression has a different aim from tissue eradication

NIDDK describes PPIs reducing stomach acid and limiting acid-related injury. AGA’s 2025 guideline conditionally favors PPI therapy for progression prevention over no therapy and over antireflux surgery used for that purpose. Improving reflux, preventing injury, eradicating dysplasia and reducing cancer deaths remain different outcomes with different evidence.[4][7]

Evidence & uncertainty

The pathology category matters. AGA’s 2024 guideline favors eradication therapy strongly for high-grade dysplasia, conditionally for low-grade dysplasia and conditionally against it without dysplasia. Surveillance also has evidence gaps. A trial in confirmed low-grade disease should not be applied to every Barrett’s diagnosis.[6]

Selected-source overview · Independent review pending

Published questions

Does Barrett’s esophagus itself mean esophageal cancer?

Selected-source overview · Independent review pending. Read the evidence context.

Most people with Barrett’s do not develop cancer.[1]

Evidence behind this answer

Definition & Facts for Barrett’s Esophagus
agency condition or prevention explanation · 2024
Selected relevant original official page passages inspected · August 2024: changed lining, risk context and dysplasia categories